JP2007516226A5 - - Google Patents

Download PDF

Info

Publication number
JP2007516226A5
JP2007516226A5 JP2006533104A JP2006533104A JP2007516226A5 JP 2007516226 A5 JP2007516226 A5 JP 2007516226A5 JP 2006533104 A JP2006533104 A JP 2006533104A JP 2006533104 A JP2006533104 A JP 2006533104A JP 2007516226 A5 JP2007516226 A5 JP 2007516226A5
Authority
JP
Japan
Prior art keywords
antibody
ovr115
pta
cells
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2006533104A
Other languages
English (en)
Japanese (ja)
Other versions
JP4884225B2 (ja
JP2007516226A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2004/015258 external-priority patent/WO2004104173A2/en
Publication of JP2007516226A publication Critical patent/JP2007516226A/ja
Publication of JP2007516226A5 publication Critical patent/JP2007516226A5/ja
Application granted granted Critical
Publication of JP4884225B2 publication Critical patent/JP4884225B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

JP2006533104A 2003-05-16 2004-05-17 Ｏｖｒ１１５抗体組成物および使用方法 Expired - Fee Related JP4884225B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US47106803P 2003-05-16 2003-05-16
US60/471,068 2003-05-16
US55973004P 2004-04-05 2004-04-05
US60/559,730 2004-04-05
PCT/US2004/015258 WO2004104173A2 (en) 2003-05-16 2004-05-17 Ovr115 ANTIBODY COMPOSITION AND METHODS OF USE

Publications (3)

Publication Number Publication Date
JP2007516226A JP2007516226A (ja) 2007-06-21
JP2007516226A5 true JP2007516226A5 (enExample) 2008-02-07
JP4884225B2 JP4884225B2 (ja) 2012-02-29

Family

ID=33479274

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2006533104A Expired - Fee Related JP4884225B2 (ja) 2003-05-16 2004-05-17 Ｏｖｒ１１５抗体組成物および使用方法

Country Status (7)

Country Link
US (2) US8207311B2 (enExample)
EP (1) EP1633850A4 (enExample)
JP (1) JP4884225B2 (enExample)
AU (1) AU2004241446B2 (enExample)
CA (1) CA2525840A1 (enExample)
IL (1) IL171798A (enExample)
WO (1) WO2004104173A2 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1633850A4 (en) * 2003-05-16 2007-04-04 Diadexus Inc OVR115 ANTIBODY COMPOSITIONS AND METHODS OF USE
JP2008522632A (ja) 2004-12-13 2008-07-03 アレシア・バイオセラピューティクス・インコーポレーテッド 骨再構築のプロセスに関与するポリヌクレオチド及びポリペプチド配列
WO2008103701A2 (en) * 2007-02-20 2008-08-28 Diadexus, Inc. Ovr115 antibody compositions and methods of use
US9616114B1 (en) 2014-09-18 2017-04-11 David Gordon Bermudes Modified bacteria having improved pharmacokinetics and tumor colonization enhancing antitumor activity
US10676723B2 (en) 2015-05-11 2020-06-09 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
US11180535B1 (en) 2016-12-07 2021-11-23 David Gordon Bermudes Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria
US11129906B1 (en) 2016-12-07 2021-09-28 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU8275998A (en) * 1997-06-27 1999-01-19 Immunetics, Inc. Rapid flow-through binding assay apparatus and method
NZ531664A (en) * 1998-09-01 2005-07-29 Genentech Inc Pro1317 polypeptides and sequences thereof with homology to the semaphorin B glycoprotein family
EP2053129A3 (en) * 1998-09-02 2009-08-19 Diadexus, Inc. Method of diagnosing, monitoring, staging, imaging and treating various cancers
US20020119158A1 (en) * 1998-12-17 2002-08-29 Corixa Corporation Compositions and methods for the therapy and diagnosis of ovarian cancer
WO2001004141A2 (en) * 1999-07-12 2001-01-18 Merck Patent Gmbh Seripancrin
US6455668B1 (en) * 2000-01-28 2002-09-24 Eos Biotechnology, Inc. Methods of diagnosing colorectal cancer, compositions, and methods of screening for colorectal cancer modulators
US6682890B2 (en) * 2000-08-17 2004-01-27 Protein Design Labs, Inc. Methods of diagnosing and determining prognosis of colorectal cancer
EP1633850A4 (en) * 2003-05-16 2007-04-04 Diadexus Inc OVR115 ANTIBODY COMPOSITIONS AND METHODS OF USE

Similar Documents

Publication Publication Date Title
JP2007504280A5 (enExample)
Trang et al. A coiled-coil masking domain for selective activation of therapeutic antibodies
Cheng et al. MORAb-202, an antibody–drug conjugate utilizing humanized anti-human FRα farletuzumab and the microtubule-targeting agent eribulin, has potent antitumor activity
JP6491701B2 (ja) 新規モジュレーターと使用の方法
JP2022106840A (ja) Ｂ細胞成熟抗原結合タンパク質
RU2627176C2 (ru) Новые модуляторы и способы их применения
JP2008532523A5 (enExample)
JP2010510809A5 (enExample)
Sokolowska-Wedzina et al. High-affinity internalizing human scFv-Fc antibody for targeting FGFR1-overexpressing lung cancer
CN111183156A (zh) 用于用抗cd19/cd20免疫治疗来治疗癌症的组合物和方法
KR20210100655A (ko) 항-클라우딘 항체 및 이의 용도
US9249223B2 (en) Humanized anti CXCR4 antibodies for the treatment of cancer
CN109422811A (zh) 抗cd47抗体及其用途
RU2015108348A (ru) Антитела, связывающиеся с лизилоксидазоподобным ферментом-2 (loxl2), и способы их применения
JP2008546780A5 (enExample)
JP2016503295A5 (enExample)
JP2017500028A (ja) 新規の抗ｄｐｅｐ３抗体および使用方法
RU2007133108A (ru) АНТИТЕЛА, СВЯЗЫВАЮЩИЕСЯ С EphA2, И МЕТОДЫ ИХ ИСПОЛЬЗОВАНИЯ
JP2012100677A5 (enExample)
JP2016116536A5 (enExample)
JP2009539380A5 (enExample)
JP2010537671A5 (enExample)
AU2011293127A1 (en) Notum protein modulators and methods of use
KR20140027051A (ko) 인간 프로스타글란딘 e2 수용체 ep4 에 대한 항체
Minami et al. Overcoming chemoresistance of small-cell lung cancer through stepwise HER2-targeted antibody-dependent cell-mediated cytotoxicity and VEGF-targeted antiangiogenesis